[go: up one dir, main page]

AR084169A1 - Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab - Google Patents

Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab

Info

Publication number
AR084169A1
AR084169A1 ARP110104553A ARP110104553A AR084169A1 AR 084169 A1 AR084169 A1 AR 084169A1 AR P110104553 A ARP110104553 A AR P110104553A AR P110104553 A ARP110104553 A AR P110104553A AR 084169 A1 AR084169 A1 AR 084169A1
Authority
AR
Argentina
Prior art keywords
cetuximab
combination
combretastatinas
family derivative
family
Prior art date
Application number
ARP110104553A
Other languages
English (en)
Inventor
Chantal Carrez
Brigitte Demers
Yvette Ruffin
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR084169A1 publication Critical patent/AR084169A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Combinación farmacéutica que comprende un derivado de la familia de las combretastatinas, tal como la ombrabulina, que puede estar en forma de base o en forma de una sal farmacéuticamente aceptable, y cetuximab.Reivindicación 2: Combinación según la reivindicación 1 en la que el derivado de la familia de las combretastatinas es AVE8062 de fórmula (1), que puede estar en forma de base o en forma de sal farmacéuticamente aceptable.
ARP110104553A 2010-12-09 2011-12-06 Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab AR084169A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1060293A FR2968557A1 (fr) 2010-12-09 2010-12-09 Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab

Publications (1)

Publication Number Publication Date
AR084169A1 true AR084169A1 (es) 2013-04-24

Family

ID=43837735

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104553A AR084169A1 (es) 2010-12-09 2011-12-06 Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab

Country Status (5)

Country Link
AR (1) AR084169A1 (es)
FR (1) FR2968557A1 (es)
TW (1) TW201306833A (es)
UY (1) UY33789A (es)
WO (1) WO2012076688A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889530A1 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
US20170128592A1 (en) * 2015-10-01 2017-05-11 Indian Institute Of Technology, Bombay Targeted polymeric nano-complexes as drug delivery system
CN112225673B (zh) * 2020-11-13 2022-08-02 义乌市华耀医药科技有限公司 氨基康普立停衍生物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
DE69931766T2 (de) 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
ATE489080T1 (de) 2001-06-25 2010-12-15 Ajinomoto Kk Antitumorale mittel
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
EP2231147A2 (en) * 2007-12-13 2010-09-29 Novartis AG Combinations of therapeutic agents for treating cancer
WO2009103076A1 (en) * 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Also Published As

Publication number Publication date
FR2968557A1 (fr) 2012-06-15
UY33789A (es) 2012-07-31
TW201306833A (zh) 2013-02-16
WO2012076688A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
ECSP13013074A (es) Nuevos derivados de piridina
AR077629A1 (es) Mimetico de smac
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
MX2014015185A (es) Derivados deuterados de ruxolitinib.
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
ECSP12012103A (es) Inhibidores de virus flaviviridae.
SV2011004019A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CU20140068A7 (es) Triazolopiridinas sustituidas
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CR20140134A (es) Composiciones farmacéuticas
CR20150250A (es) Nuevos derivados de piridina
CR20150204A (es) Nuevos derivados de piridina
HRP20182043T1 (hr) Upotreba anti-konfeksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
CR20110219A (es) Ácidos naftilacéticos
UY32404A (es) 4-aril-butan-1,3-diamidas
UY33794A (es) Inhibidores diméricos de las iap
CO6390102A2 (es) Combinacion anitumoral que comprende ave8062 y sorafenib
UY33236A (es) Inhibidores dimericos de las iap
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
AR082215A1 (es) Composicion farmaceutica agradable al paladar
EA201490199A1 (ru) Терапевтические способы
CU20140028A7 (es) Compuesto de benzotiazolona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal